ALSMA Stock Overview
Provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
S.M.A.I.O S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.32 |
| 52 Week High | €4.34 |
| 52 Week Low | €2.14 |
| Beta | 0.52 |
| 11 Month Change | 16.76% |
| 3 Month Change | 35.85% |
| 1 Year Change | 71.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.44% |
Recent News & Updates
Shareholder Returns
| ALSMA | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 1.2% | 7.1% | 0.04% |
| 1Y | 71.4% | 12.8% | -3.6% |
Return vs Industry: ALSMA exceeded the French Medical Equipment industry which returned 7% over the past year.
Return vs Market: ALSMA exceeded the French Market which returned -4.7% over the past year.
Price Volatility
| ALSMA volatility | |
|---|---|
| ALSMA Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: ALSMA's share price has been volatile over the past 3 months.
Volatility Over Time: ALSMA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 36 | Philippe Roussouly | smaio.com |
S.M.A.I.O S.A. provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery. The company was incorporated in 2009 and is based in Saint-Priest, France.
S.M.A.I.O S.A. Fundamentals Summary
| ALSMA fundamental statistics | |
|---|---|
| Market cap | €22.53m |
| Earnings (TTM) | €1.06m |
| Revenue (TTM) | €8.75m |
21.3x
P/E Ratio2.6x
P/S RatioIs ALSMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSMA income statement (TTM) | |
|---|---|
| Revenue | €8.75m |
| Cost of Revenue | €3.48m |
| Gross Profit | €5.27m |
| Other Expenses | €4.21m |
| Earnings | €1.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Oct 15, 2024
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 60.25% |
| Net Profit Margin | 12.10% |
| Debt/Equity Ratio | 28.3% |
How did ALSMA perform over the long term?
See historical performance and comparison